NDC 49702-238-64 - Cabenuva
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 49702-238
- Requested NDC
- 49702-238-64
- Package NDCs from labels
- 49702-238-01, 49702-238-64, 49702-238-03, 49702-238-61
- Manufacturer
- ViiV Healthcare Company | Glaxo Wellcome Manufacturing Pte. Ltd | Janssen Pharmaceutica NV
- Effective date
- 2025-11-26
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Cabenuva - ViiV Healthcare Company | Glaxo Wellcome Manufacturing Pte. Ltd | Janssen Pharmaceutica NV | ViiV Healthcare Company | Glaxo Wellcome Manufacturing Pte. Ltd | Janssen Pharmaceutica NV | 2025-11-26 | HUMAN PRESCRIPTION DRUG LABEL |
| Apretude - ViiV Healthcare Company | ViiV Healthcare Company | 2025-04-11 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 49702-238-01 | Cabenuva | 3 mL in 1 VIAL | INJECTION, SUSPENSION, EXTENDED | 1 mL | 200 mg in 1mL | 16 |
| 49702-238-64 | Cabenuva | 3 mL in 1 VIAL | INJECTION, SUSPENSION, EXTENDED | 1 mL | 200 mg in 1mL | 16 |
| 49702-238-03 | Apretude | 3 mL in 1 VIAL | INJECTION, SUSPENSION, EXTENDED | 3 mL | 200 mg in 1mL | 8 |
| 49702-238-61 | Apretude | 3 mL in 1 VIAL | INJECTION, SUSPENSION, EXTENDED | 3 mL | 200 mg in 1mL | 8 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 49702-238 | CABENUVA (CABOTEGRAVIR AND RILPIVIRINE) KIT [VIIV HEALTHCARE COMPANY] | 14 | Unmatched | 20250416_1698baf3-f895-4c42-a1b1-e9ee3f20da36.zip |
| 49702-238 | APRETUDE (CABOTEGRAVIR) KIT [VIIV HEALTHCARE COMPANY] | 8 | Unmatched | 20250419_4338428e-43d4-4e02-ac9d-bd98e738a7da.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Dextrose | DEXTROSE | B. Braun Medical Inc. | 60b6d7c3-0164-46c9-aa38-b5aa1c31a5d5 | 2026-05-12 | Warnings, Adverse reactions | LX22YL083G |
| Polyethylene glycol 3350 | POLYETHYLENE GLYCOL 3350 | Major Pharmaceuticals | ddc9d2b1-87d8-44fa-bac6-0a7261f33564 | 2026-05-12 | Warnings | G2M7P15E5P |
| Sterile Water | STERILE WATER | Nephron Pharmaceuticals Corporation | bc04a883-babc-87a6-e053-2995a90a3dfd | 2026-05-08 | Warnings, Adverse reactions | 059QF0KO0R |
| smooth lax | POLYETHYLENE GLYCOL 3350 | Walgreen Company | 3027af65-2f7f-472d-83f5-254d5d75013c | 2026-05-08 | Warnings | G2M7P15E5P |
| Sterile Water | WATER | Hospira, Inc. | 3a6422e1-feee-4095-8883-2b0837039e6e | 2026-05-07 | Warnings, Adverse reactions | 059QF0KO0R |
| Multi Flower | AESCULUS CARNEA, FLOS, AESCULUS HIPPOCASTANUM, FLOS, AGRIMONIA EUPATORIA, FLOS, BROMUS RAMOSUS, FLOS, CALLUNA VULGARIS, FLOS, CARPINUS BETULUS , FLOS, CASTANEA SATIVA, FLOS, CENTAURIUM UMBELLATUM, FLOS, CERATOSTIGMA WILLMOTTIANUM, FLOS, CICHORIUM INTYBUS, FLOS, CLEMATIS VITALBA, FLOS, CLEMATIS VITALBA, FLOS, FAGUS SYLVATICA, FLOS, GENTIANELLA AMARELLA, FLOS, HELIANTHEMUM NUMMULARIUM, FLOS, ILEX AQUIFOLIUM, FLOS, IMPATIENS GLANDULIFERA, FLOS, LARIX DECIDUA, FLOS, LONICERA CAPRIFOLIUM, FLOS | Energique, Inc. | 09c059e7-f748-402c-8447-af5b61169c58 | 2026-05-06 | Warnings | 059QF0KO0R |
| MiraLAX | POLYETHYLENE GLYCOL 3350 | Bayer HealthCare LLC. | d69ce3d4-7ca4-4fe3-b49e-6655e48d6963 | 2026-05-04 | Warnings | G2M7P15E5P |
| GAVILAX | POLYETHYLENE GLYCOL 3350 | Preferred Pharmaceuticals, Inc. | 21654def-5ae0-422d-961b-1fe2456af00a | 2026-05-04 | Warnings | G2M7P15E5P |
| POLYETHYLENE GLYCOL 3350 | POLYETHYLENE GLYCOL 3350 | CARDINAL HEALTH 110, LLC. DBA LEADER | 04cc4f2e-1725-4710-8cfb-73a6bdf52e4f | 2026-04-23 | Warnings | G2M7P15E5P |
| Polyethylene Glycol 3350 | POLYETHYLENE GLYCOL 3350 | Aurobindo Pharma Limited | b51f2223-8266-4d6c-bf32-58e53e73b54d | 2026-04-23 | Warnings | G2M7P15E5P |
| COMFORTLAX | POLYETHYLENE GLYCOL 3350 | Family Dollar Stores, LLC | 02a44a41-0039-f6ec-e063-6394a90ae6f1 | 2026-04-23 | Warnings | G2M7P15E5P |
| Polyethylene Glycol 3350 | POLYETHYLENE GLYCOL 3350 | Aurohealth LLC | d3c77f3f-57aa-4e2d-88aa-731cbb22af70 | 2026-04-23 | Warnings | G2M7P15E5P |
| Mannitol | MANNITOL | Hospira, Inc. | 8ad3145e-00e7-4412-b9a5-06f00f264f30 | 2026-04-21 | Warnings, Adverse reactions | 3OWL53L36A |
| PEG 3350 and Electrolytes | POLYETHYLENE GLYCOL 3350, SODIUM SULFATE ANHYDROUS, SODIUM BICARBONATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE | Wilshire Pharmaceuticals, Inc. | b251752d-7750-482a-9364-0acf4ad47cc8 | 2026-04-16 | Warnings, Adverse reactions | G2M7P15E5P |
| Dextrose and Sodium Chloride | DEXTROSE MONOHYDRATE AND SODIUM CHLORIDE | Fresenius Kabi USA, LLC | 99c6a1a9-cadf-435b-a332-ccc189afdfa9 | 2026-04-16 | Warnings, Adverse reactions | LX22YL083G |
| GoLYTELY | POLYETHYLENE GLYCOL 3350, SODIUM SULFATE ANHYDROUS, SODIUM BICARBONATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE | Azurity Pharmaceuticals, Inc. | 7609ecf7-0ce0-4fbb-9c27-30987f689575 | 2026-04-15 | Warnings, Adverse reactions | G2M7P15E5P |
| TRILYTE | POLYETHYLENE GLYOCOL 3350, SODIUM CHLORIDE, SODIUM BICARBONATE AND POTASSIUM CHLORIDE | Aurobindo Pharma Limited | 79f5e596-8d51-4227-afcc-f5e341150957 | 2026-04-15 | Warnings, Adverse reactions | G2M7P15E5P |
| PEG 3350, sodium chloride, sodium bicarbonate and potassium chloride | POLYETHYLENE GLYCOL 3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE | Wilshire Pharmaceuticals, Inc. | 4e442a72-b13b-4869-8a1d-59356095b091 | 2026-04-14 | Warnings, Adverse reactions | G2M7P15E5P |
| clear lax | POLYETHYLENE GLYCOL 3350 | Meijer Distribution Inc | 6464f12c-0883-46c5-943b-a84fe235588e | 2026-04-13 | Warnings | G2M7P15E5P |
| Dextrose | DEXTROSE MONOHYDRATE | Henry Schein, Inc. | 40fd1ac4-39bb-45fb-ba99-4fb65481f231 | 2026-04-09 | Warnings, Adverse reactions | LX22YL083G |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.